The company is set to release topline results from its Phase 3 superiority trial of Axpaxli in wet AMD on Tuesday. ・Ocular previously said that positive results could support a New Drug Application ...

Researchers reviewed the phase 3 findings of a TKI inhibitor treatment compared with aflibercept 2 mg for maintaining vision in patients with wet AMD.

Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched position in wet age-related macular degeneration (AMD) with investigational | ...

Rapid drying of retinal fluid with faricimab injections may help identify patients with neovascular age-related macular degeneration who can safely extend time between injections.

Julie Rosenthal, MD, MS, discusses the future direction of research into treating age-related macular degeneration.

Newmedica Oxfordshire is highlighting the signs of age-related macular degeneration (AMD) during AMD Awareness Month and is calling for the NHS to publish clearer data on its waiting lists for AMD ...

Newmedica Worcester highlights AMD Awareness Month, urging early detection of age-related macular degeneration—the UK’s leading cause of ...